The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment
← catalyst calendarNCT07643896 · readout ≤ 498 d
Sponsored by BillionToOne Inc. (industry) · BLLN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
1,000estimated
Sites
6
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-10 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Pregnant Individuals
- Aneuploidy
- Down Syndrome (Trisomy 21)
- 22q11.2 Deletion Syndrome
- Trisomy 13
- Trisomy 18
- Sex Chromosome Abnormalities
Primary outcomes
what the primary-completion date above is the date OFConcordance
measured From enrollment and up to 12 months following enrollment
Concordance with the accepted method of diagnosis
measured From enrollment and up to 12 months following enrollment
Permalink · BLLN's whole pipeline · Catalyst calendar · Every registered study · What changed